How Zeelab Is Turning Its Affordable Pharma Play Into A ₹200 Cr Business
Affordable medicines remain Zeelab’s core USP, with the company cutting intermediaries to offer products at significantly lower prices
The full text for this story couldn't be loaded here — read it at the verified source below.
Verified source · Inc42
Reported by Inc42. Open the original for full media and formatting.
More in India
All news
IndiaTCS HyperVault To Invest ₹70,000 Cr To Set Up AI Data Centre in Hyderabad
Tata Consultancy Services’ (TCS) data centre subsidiary, HyperVault, and its partners will invest up to ₹70,000 Cr to build and…
Read at Inc42
IndiaD2C Luggage Brand Mokobara Bags ₹170 Cr
Travel and lifestyle brand Mokobara has raised ₹170 Cr (about $18 Mn) in a Series C funding round led by Sauce.vc
Read at Inc42
IndiaFY26 Financial Tracker: Tracking The Financial Performance Of Indian Startups
The Indian startup ecosystem continued to mature in FY26, with 22 new-age tech companies making their public market debut as…
Read at Inc42
IndiaOla Electric Board Approves Fresh ₹1,500 Cr Fundraise After ₹780 Cr QIP
Ola Electric’s board has approved a fresh fundraise of up to ₹1,500 Cr, three months after the company raised ₹780 Cr through a QIP.
Read at Inc42